Wai Yuen Tong Medicine Holdings Limited has announced its final results for the year ended 31 March 2025. The company reported a revenue from continuing operations of HK$745.3 million, a decrease of 4.9% compared to HK$783.9 million in the previous year. The gross profit from continuing operations also saw a decline of 4.6%, amounting to HK$376.5 million, down from HK$394.8 million. The profit for the year showed a significant increase of 77.5%, reaching HK$7.1 million from HK$4.0 million in the prior year. Earnings per share rose by 148.5%, from a loss of 1.30 HK cents to a positive 0.63 HK cents. The net assets value as of 31 March 2025 was reported at HK$1,179.6 million, marking a decline of 14.9% from HK$1,385.5 million as of the previous year-end. Additionally, cash and cash equivalents decreased by 14.6% to HK$132.3 million. The gearing ratio improved, dropping from 21.7% to 17.9%. No outlook or guidance for future periods was provided in the announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.